Literature DB >> 1515715

Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report.

M V Beheshti1, D F Denny, M G Glickman, W Bodden, J C Marsh, R Strair, T S Ravikumar.   

Abstract

Chemotherapy for primary or metastatic hepatic malignancy is limited by poor tumor response and dose-related systemic toxicity. As an alternative to chemotherapy infusion by vein or by the hepatic artery, the authors have developed a percutaneous technique of isolated liver perfusion that allows the regional delivery of high-dose chemotherapy to the liver with little systemic toxicity. After placement of a hepatic artery infusion catheter, an 18-F double-balloon catheter is placed into the inferior vena cava through the opposite femoral vein. Balloons are inflated above and below the hepatic veins, thus isolating hepatic venous outflow. The effluent passes through fenestrations in the catheter and is pumped through charcoal hemoperfusion filters where the drug is removed. The filtered blood is returned to the patient through the internal jugular vein. Fifteen treatments have been conducted in eight patients in a phase I dose-escalation study with use of 5-fluorouracil (5-FU). While it is premature to assess tumor response to isolated liver perfusion, the data demonstrate that the procedure is safe and is tolerated by patients. Pharmacokinetic studies show a 5-FU extraction of up to 85%, with minimal drug leakage into the systemic circulation. This technique shows potential for improving liver tumor response while decreasing systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515715     DOI: 10.1016/s1051-0443(92)71988-5

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  10 in total

1.  Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model.

Authors:  Geert Maleux; Diethard Monbaliu; Chris Verslype; Christophe Casteleyn; Marc Van De Velde; Pieter Cornillie; Yvonne Hoogeveen; Eric Van Cutsem
Journal:  Eur Radiol       Date:  2010-05-22       Impact factor: 5.315

2.  Retrograde-outflow percutaneous isolated hepatic perfusion using cisplatin: A pilot study on pharmacokinetics and feasibility.

Authors:  Satoru Murata; Shiro Onozawa; Takahiko Mine; Tatsuo Ueda; Fumie Sugihara; Daisuke Yasui; Shin-Ichiro Kumita; Mitsuo Satake
Journal:  Eur Radiol       Date:  2014-12-18       Impact factor: 5.315

Review 3.  Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.

Authors:  Dale Han; Georgia M Beasley; Douglas S Tyler; Jonathan S Zager
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-10-07       Impact factor: 4.481

4.  Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma.

Authors:  Ilan Ben-Shabat; Christoffer Hansson; Malin Sternby Eilard; Christian Cahlin; Magnus Rizell; Per Lindnér; Jan Mattsson; Roger Olofsson Bagge
Journal:  J Vis Exp       Date:  2015-01-25       Impact factor: 1.355

Review 5.  Isolated hepatic perfusion for patients with liver metastases.

Authors:  Srinevas K Reddy; Susan B Kesmodel; H Richard Alexander
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

Review 6.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

7.  Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.

Authors:  Meghan R Forster; Omar M Rashid; Matthew C Perez; Junsung Choi; Tariq Chaudhry; Jonathan S Zager
Journal:  J Surg Oncol       Date:  2013-11-19       Impact factor: 3.454

Review 8.  A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System.

Authors:  Pier Francesco Ferrucci; Emilia Cocorocchio; Guido Bonomo; Gianluca Maria Varano; Paolo Della Vigna; Franco Orsi
Journal:  Cells       Date:  2021-01-05       Impact factor: 6.600

9.  Pilot study of transcatheter arterial ethanol embolization under closed renal circuit for large renal cell carcinomas.

Authors:  Satoru Murata; Hiroyuki Tajima; Shiro Onozawa; Shinichiro Kumita; Yukihiro Kondo; Kazuhiro Nomura
Journal:  Eur Radiol       Date:  2008-03-20       Impact factor: 7.034

10.  Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Authors:  Roger Olofsson; Lars Ny; Malin Sternby Eilard; Magnus Rizell; Christian Cahlin; Ulrika Stierner; Ulf Lönn; Johan Hansson; Ingrid Ljuslinder; Lotta Lundgren; Gustav Ullenhag; Jens Folke Kiilgaard; Jonas Nilsson; Per Lindnér
Journal:  Trials       Date:  2014-08-09       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.